Thus, this suggested a hypothesis that dual therapy using available anti CD200+ neutralizing antibody in combination with Smo antagonists would be a novel strategy for a complete inhibition of BCC progression [164]. The gene discussed is CD200; the disease is skin basal cell carcinoma.